Kristian Reich
Impact in
- Dermatology top 0.01%
- Dermatology and Skin Diseases
- Immunology top 0.02%
- Psoriasis: Treatment and Pathogenesis
Papers in
- Immunology 356
- Psoriasis: Treatment and Pathogenesis 333
- Dermatology 154
- Dermatology and Skin Diseases 136
- Co-authors
- Kim Papp (63 shared papers)Richard G. Langley (73 shared papers)Matthias Augustin (81 shared papers)C.E.M. Griffiths (32 shared papers)Mark Lebwohl (53 shared papers)Andrew Blauvelt (84 shared papers)Diamant Thaçi (56 shared papers)Ulrich Mrowietz (76 shared papers)
- Journals
- British Journal of Dermatology (69 papers)JDDG Journal der Deutschen Dermatologischen Gesellschaft (56 papers)Journal of the European Academy of Dermatology and Venereology (54 papers)Journal of the American Academy of Dermatology (44 papers)Journal of Investigative Dermatology (23 papers)
- Partner nations
- GermanyUnited StatesCanada
In The Last Decade
Kristian Reich
475 papers receiving 26.2k citations
Kristian Reich's Hit Papers
Peers
Comparison fields: 5 of 147
- Dermatology 8.8k
- Immunology 18.8k
- Rheumatology 4.0k
- Immunology and Allergy 1.4k
- Hematology 1.7k
Countries citing papers authored by Kristian Reich
This map shows the geographic impact of Kristian Reich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kristian Reich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kristian Reich more than expected).
Fields of papers citing papers by Kristian Reich
This network shows the impact of papers produced by Kristian Reich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kristian Reich. The network helps show where Kristian Reich may publish in the future.
Co-authors
The 25 scholars most cited alongside Kristian Reich, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 500 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials Hit paper breakdown → | 2014 | 1511 |
| 2 | Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) Hit paper breakdown → | 2008 | 1070 |
| 3 | Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial Hit paper breakdown → | 2005 | 837 |
| 4 | Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis Hit paper breakdown → | 2016 | 666 |
| 5 | Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials Hit paper breakdown → | 2015 | 664 |
| 6 | Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial Hit paper breakdown → | 2017 | 546 |
| 7 | Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1) Hit paper breakdown → | 2015 | 488 |
| 8 | 2015 | 432 | |
| 9 | Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials Hit paper breakdown → | 2017 | 425 |
| 10 | 2014 | 415 | |
| 11 | 2016 | 384 | |
| 12 | 2009 | 358 | |
| 13 | Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t Hit paper breakdown → | 2017 | 351 |
| 14 | 2013 | 317 | |
| 15 | 2009 | 286 | |
| 16 | 2012 | 271 | |
| 17 | 2019 | 271 | |
| 18 | Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2021 | 264 |
| 19 | Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial Hit paper breakdown → | 2019 | 261 |
| 20 | 2010 | 259 |
About Kristian Reich
Kristian Reich is a scholar working on Immunology, Dermatology, Rheumatology, Pathology and Forensic Medicine and Pediatrics, Perinatology and Child Health, having authored 500 papers that have together received 26.8k indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (333 papers), Dermatology and Skin Diseases (136 papers), Autoimmune Bullous Skin Diseases (47 papers), Pharmaceutical studies and practices (35 papers), Asthma and respiratory diseases (33 papers), Spondyloarthritis Studies and Treatments (32 papers), Health Systems, Economic Evaluations, Quality of Life (31 papers) and Urticaria and Related Conditions (17 papers). The work is most often cited by research in Dermatology (8.8k citations), Immunology (18.8k citations), Rheumatology (4.0k citations), Immunology and Allergy (1.4k citations) and Hematology (1.7k citations). Kristian Reich has collaborated with scholars based in Germany, United States and Canada. Frequent co-authors include Kim Papp, Richard G. Langley, Matthias Augustin, C.E.M. Griffiths, Mark Lebwohl, Andrew Blauvelt, Diamant Thaçi, Ulrich Mrowietz, Shu Li and Marc Alexander Radtke. Their work appears in journals such as British Journal of Dermatology, JDDG Journal der Deutschen Dermatologischen Gesellschaft, Journal of the European Academy of Dermatology and Venereology, Journal of the American Academy of Dermatology and Journal of Investigative Dermatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.